| Item type |
学位論文 / Thesis or Dissertation(1) |
| 公開日 |
2020-08-26 |
| タイトル |
|
|
タイトル |
Re-irradiation for locoregionally recurrent tumors of the thorax: a single-institution, retrospective study |
| タイトル |
|
|
タイトル |
Re-irradiation for locoregionally recurrent tumors of the thorax: a single-institution, retrospective study |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_46ec |
|
資源タイプ |
thesis |
| 別タイトル |
|
|
その他のタイトル |
局所再発胸部腫瘍に対する再照射についての単施設・後方視的検討 |
| 著者 |
角田, 貴代美
Sumita, Kiyomi
Harada, Hideyuki
Asakura, Hirofumi
Ogawa, Hirofumi
Onoe, Tsuyoshi
Murayama, Shigeyuki
Nakamura, Satoaki
Tanigawa, Noboru
Takahashi, Toshiaki
Nishimura, Tetsuo
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background
Re-irradiation (re-RT) of the thorax is challenging due to the impact of prior therapies on normal tissues, and there are few reports of definitive re-RT. The treatment toxicities and efficacy of re-RT are not well known. The aim of the present study was to assess the safety and efficacy of definitive re-RT of the thorax.
Methods
Patients who were treated with thoracic re-RT between March 2007 and December 2014 were retrospectively analyzed. Primary and re-irradiation plans were required to have an overlap of dose distributions for the 80 % isodose level. All doses were recalculated to an equivalent dose of 2 Gy per fraction (EQD2). When possible, analysis of dose accumulation was carried out using the medical image merge (MIM) (®) software program (version 6.5, MIM Software Inc., Cleveland, OH). Administration dosages for organs at risk were defined.
Results
Fourteen (67 %) and seven (33 %) patients with non-small cell carcinoma (NSCLC) and small cell carcinoma (SCLC), respectively, were identified. The patients’ median age was 72 (range 53–85) years. Fifteen patients (71 %) had “proximal” tumors, defined as tumors at the distal 2 cm of the trachea, carina, and main bronchi. The median interval from initial RT to re-RT was 26.8 (range 11.4–92.3) months. Re-RT was delivered by X-ray beam and proton beam therapy in 20 (95 %) patients and 1 (5 %) patient, respectively. The median radiation dose of re-RT was 60 (range 54–87.5) Gy10 and 50 (range 50.0–87.5) Gy10 for patients with NSCLC and SCLC, respectively. Grade 3 acute radiation pneumonitis occurred in only one patient. There were no other serious complications. The median follow-up time was 22.1 (range 2.3–56.4) months. The median local progression-free survival time (LPFS) and overall survival time (OS) were 12.9 (95 % confidence interval (CI): 8.9–27.9) months and 31.4 (95 % CI: 16.9–45.9) months, respectively. Patients receiving ≥ 60 Gy10 at re-RT had longer LPFS (p = 0.04).
Conclusions
Good safety with longer OS than in previous reports was demonstrated. Re-RT seems to be a promising treatment option. Further study to define the risk-benefit ratios is necessary. |
| 学位名 |
|
|
学位名 |
博士(医学) |
| 学位授与機関 |
|
|
|
学位授与機関名 |
関西医科大学 |
| 学位授与年度 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
平成29年度 |
| 学位授与年月日 |
|
|
学位授与年月日 |
2018-03-27 |
| 学位授与番号 |
|
|
学位授与番号 |
課博第1015号 |
| 書誌情報 |
Radiation Oncology
en : Radiation Oncology
巻 11,
号 1,
発行日 2016
|
| DOI |
|
|
|
10.1186/s13014-016-0673-z |
|
|
https://doi.org/10.1186/s13014-016-0673-z |
論文要旨（要約） (139.9 kB)
